4.7 Article

Centers for Disease Control and Prevention Initiatives to Prevent Hepatitis C Virus Infection: A Selective Update

期刊

CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S49-S53

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis363

关键词

-

资金

  1. Abbott Laboratories
  2. Boehringer Ingelheim
  3. Bristol-Myers Squibb
  4. Genentech (Roche)
  5. Gilead Sciences
  6. GlaxoSmithKline
  7. Janssen Therapeutics
  8. Merck Sharp Dohme
  9. OraSure Technologies
  10. Vertex Pharmaceuticals
  11. Viral Hepatitis Action Coalition of the CDC Foundation

向作者/读者索取更多资源

Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing and treatment, and the prospect of increasing incidence associated with the epidemic of injection drug use. Three-quarters of chronic HCV infections occur among persons born from 1945 through 1965. Prevention efforts are complicated by limited knowledge among health care professionals, persons at risk and in the public at large. At the Centers for Disease Control and Prevention, efforts to improve primary and secondary prevention effectiveness center on policy development, education and training initiatives, and applied research. This report provides a brief overview of some of these efforts, including the development of testing recommendations for the 1945-1965 birth cohort, research and evaluation studies in settings where persons who inject drugs receive services, and a national viral hepatitis education campaign that targets health care professionals, the public, and persons at risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据